Physician profile
Rocklan D Walker
NPI 1629009881
$1,456.09
in general payments reported to CMS, 2019-2025
27 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $112 · 2021: $169 · 2022: $262 · 2023: $169 · 2024: $282 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $196.31 | 2019-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $142.25 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $139.23 | 2019-2024 | Airsupra |
| Merck Sharp & Dohme LLC | $121.25 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbvie INC. | $105.14 | 2021-2022 | |
| Novo Nordisk INC | $84.23 | 2022-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.47 | 2021-2023 | |
| Pfizer INC. | $68.37 | 2019-2025 | |
| Glaxosmithkline, LLC. | $58.36 | 2023-2024 | Shingrix |
| Amgen INC. | $48.16 | 2019-2020 | |
| Inspire Medical Systems, INC. | $43.03 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $42.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $42.26 | 2019-2021 | |
| Shield Therapeutics INC | $35.29 | 2024 | |
| Amarin Pharma, INC. | $34.02 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $30.90 | 2019 | |
| Idorsia Pharmaceuticals US INC | $24.55 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $24.27 | 2022 | |
| Corcept Therapeutics | $20.81 | 2022 | |
| Sanofi Pasteur INC. | $20.08 | 2023 | |
| Circassia INC. | $17.61 | 2019 | |
| Genentech USA, INC. | $16.33 | 2019 | |
| Endo Pharmaceuticals INC. | $14.84 | 2019 | |
| Hologic Sales and Service, LLC | $14.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2025 | Zoryve |
| Nabriva Therapeutics, Plc | $12.92 | 2020 | |
| Allergan, INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocklan Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.